Gland Pharma informs about conclusion of US FDA inspection at pashamylaram facility

26 Sep 2023 Evaluate
Further to intimation dated June 27, 2023, Gland Pharma has informed that following the Pre-Approval Inspection (PAI) for Seven (7) products and Good Manufacturing Practice (GMP) Inspection by US FDA at the Company’s Pashamylaram Facility at Hyderabad between 15th June, 2023 and 27th June, 2023, the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

The above information is a part of company’s filings submitted to BSE.

Gland Pharma Share Price

1681.95 -39.70 (-2.31%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×